Search

Your search keyword '"Miller, Austin"' showing total 1,094 results
Start Over Author "Miller, Austin"
1,094 results on '"Miller, Austin"'

3. Development and Evaluation of an Accelerometer-Based Protocol for Measuring Physical Activity Levels in Cancer Survivors: Development and Usability Study

Author

Crane, Tracy E, Skiba, Meghan B, Miller, Austin, Garcia, David O, and Thomson, Cynthia A

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundThe collection of self-reported physical activity using validated questionnaires has known bias and measurement error. ObjectiveAccelerometry, an objective measure of daily activity, increases the rigor and accuracy of physical activity measurements. Here, we describe the methodology and related protocols for accelerometry data collection and quality assurance using the Actigraph GT9X accelerometer data collection in a convenience sample of ovarian cancer survivors enrolled in GOG/NRG 0225, a 24-month randomized controlled trial of diet and physical activity intervention versus attention control. MethodsFrom July 2015 to December 2019, accelerometers were mailed on 1337 separate occasions to 580 study participants to wear at 4 time points (baseline, 6, 12, and 24 months) for 7 consecutive days. Study staff contacted participants via telephone to confirm their availability to wear the accelerometers and reviewed instructions and procedures regarding the return of the accelerometers and assisted with any technology concerns. ResultsWe evaluated factors associated with wear compliance, including activity tracking, use of a mobile app, and demographic characteristics with chi-square tests and logistic regression. Compliant data, defined as ≥4 consecutive days with ≥10 hours daily wear time, exceeded 90% at all study time points. Activity tracking, but no other characteristics, was significantly associated with compliant data at all time points (P

Published
2020
Full Text
View/download PDF

4. Destabilized reporters for background-subtracted, chemically-gated, and multiplexed deep-tissue imaging

Author

Yun, Jason, Huang, Yimeng, Miller, Austin DC, Chang, Brandon L, Baldini, Logan, Dhanabalan, Kaamini M, Li, Eugene, Li, Honghao, and Mukherjee, Arnab

Subjects
Chemical Sciences, Biotechnology, Bioengineering, Genetics, Biomedical Imaging, Chemical sciences
Abstract

Tracking gene expression in deep tissues requires genetic reporters that can be unambiguously detected using tissue penetrant techniques. Magnetic resonance imaging (MRI) is uniquely suited for this purpose; however, there is a dearth of reporters that can be reliably linked to gene expression with minimal interference from background tissue signals. Here, we present a conceptually new method for generating background-subtracted, drug-gated, multiplex images of gene expression using MRI. Specifically, we engineered chemically erasable reporters consisting of a water channel, aquaporin-1, fused to destabilizing domains, which are stabilized by binding to cell-permeable small-molecule ligands. We showed that this approach allows for highly specific detection of gene expression through differential imaging. In addition, by engineering destabilized aquaporin-1 variants with orthogonal ligand requirements, it is possible to distinguish distinct subpopulations of cells in mixed cultures. Finally, we demonstrated this approach in a mouse tumor model through differential imaging of gene expression with minimal background.

Published
2024

6. Ego-Exo4D: Understanding Skilled Human Activity from First- and Third-Person Perspectives

Author

Grauman, Kristen, Westbury, Andrew, Torresani, Lorenzo, Kitani, Kris, Malik, Jitendra, Afouras, Triantafyllos, Ashutosh, Kumar, Baiyya, Vijay, Bansal, Siddhant, Boote, Bikram, Byrne, Eugene, Chavis, Zach, Chen, Joya, Cheng, Feng, Chu, Fu-Jen, Crane, Sean, Dasgupta, Avijit, Dong, Jing, Escobar, Maria, Forigua, Cristhian, Gebreselasie, Abrham, Haresh, Sanjay, Huang, Jing, Islam, Md Mohaiminul, Jain, Suyog, Khirodkar, Rawal, Kukreja, Devansh, Liang, Kevin J, Liu, Jia-Wei, Majumder, Sagnik, Mao, Yongsen, Martin, Miguel, Mavroudi, Effrosyni, Nagarajan, Tushar, Ragusa, Francesco, Ramakrishnan, Santhosh Kumar, Seminara, Luigi, Somayazulu, Arjun, Song, Yale, Su, Shan, Xue, Zihui, Zhang, Edward, Zhang, Jinxu, Castillo, Angela, Chen, Changan, Fu, Xinzhu, Furuta, Ryosuke, Gonzalez, Cristina, Gupta, Prince, Hu, Jiabo, Huang, Yifei, Huang, Yiming, Khoo, Weslie, Kumar, Anush, Kuo, Robert, Lakhavani, Sach, Liu, Miao, Luo, Mi, Luo, Zhengyi, Meredith, Brighid, Miller, Austin, Oguntola, Oluwatumininu, Pan, Xiaqing, Peng, Penny, Pramanick, Shraman, Ramazanova, Merey, Ryan, Fiona, Shan, Wei, Somasundaram, Kiran, Song, Chenan, Southerland, Audrey, Tateno, Masatoshi, Wang, Huiyu, Wang, Yuchen, Yagi, Takuma, Yan, Mingfei, Yang, Xitong, Yu, Zecheng, Zha, Shengxin Cindy, Zhao, Chen, Zhao, Ziwei, Zhu, Zhifan, Zhuo, Jeff, Arbelaez, Pablo, Bertasius, Gedas, Crandall, David, Damen, Dima, Engel, Jakob, Farinella, Giovanni Maria, Furnari, Antonino, Ghanem, Bernard, Hoffman, Judy, Jawahar, C. V., Newcombe, Richard, Park, Hyun Soo, Rehg, James M., Sato, Yoichi, Savva, Manolis, Shi, Jianbo, Shou, Mike Zheng, and Wray, Michael

Subjects
Computer Science - Computer Vision and Pattern Recognition, Computer Science - Artificial Intelligence
Abstract

We present Ego-Exo4D, a diverse, large-scale multimodal multiview video dataset and benchmark challenge. Ego-Exo4D centers around simultaneously-captured egocentric and exocentric video of skilled human activities (e.g., sports, music, dance, bike repair). 740 participants from 13 cities worldwide performed these activities in 123 different natural scene contexts, yielding long-form captures from 1 to 42 minutes each and 1,286 hours of video combined. The multimodal nature of the dataset is unprecedented: the video is accompanied by multichannel audio, eye gaze, 3D point clouds, camera poses, IMU, and multiple paired language descriptions -- including a novel "expert commentary" done by coaches and teachers and tailored to the skilled-activity domain. To push the frontier of first-person video understanding of skilled human activity, we also present a suite of benchmark tasks and their annotations, including fine-grained activity understanding, proficiency estimation, cross-view translation, and 3D hand/body pose. All resources are open sourced to fuel new research in the community. Project page: http://ego-exo4d-data.org/, Comment: Expanded manuscript (compared to arxiv v1 from Nov 2023 and CVPR 2024 paper from June 2024) for more comprehensive dataset and benchmark presentation, plus new results on v2 data release

Published
2023

7. Artists' Statements

Author

Arcangel, Cory, Daggett, Mark, Epuré, Serban, Huff, Kenneth A, Lichty, Patrick, Miller, Austin, Miller, Dennis, Polli, Andrea, Smith, Kathy, Snyder, Mark J, Swiss, Thomas, Giordano, Skye, and Wei, Liu

Published
2001

8. Gallery Artworks

Author

Geib, Dona J, Millstein, Mark, Epuré, Serban, Wright, Richard, Rubin, Cynthia Beth, Koen, Viktor, Doherty, Robin, Ross, Tim, Porett, Thomas, Chambers, Tom, Field, Michael, Whitaker, Corinne, McGee, Nancy, Reiser, Michaela, King, Mike, Huff, Kenneth A, Leigh, Dennis, Boakes, Jonathan, Pamula, Jan, Miller, Austin, Mitchell, Bonnie, Anderson, Victor, Wei, Liu, Lleo, Juan Antonio, Miller, Dennis, Gonzalez, Quintin, Snyder, Mark J, Teipen, Jeremiah, Diosi, Ivor, Casado, Jose Carlos, Kobayashi, Keiko, Erickson, Christa, Walker, James Faure, Hovagimyan, G. H, Sinclair, Peter, Kim, Shin Il, Kim, Yunchul, Abahuni, Leesa, Abahuni, Nicole, Wechsler, Robert, Rovan, Butch, Weiss, Frieder, Arcangel, Cory, Ashford, Rain Anne, Chiang, Nancy, Saigal, Aishwarya, Colson, Richard, Minami, Hidekazu, Lattanzi, Barbara, Glaser, Michelle, Hutchison, Andrew, Xavier, Marie-Louise, Rahn, James, Kaline, Sasha, and Chrysakis, Thanos

Published
2001

9. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Author

Lee, Jung-Min, Brady, Mark F., Miller, Austin, Moore, Richard G., MacKay, Helen, McNally, Leah, Lea, Jayanthi, Street, Daron, Lheureux, Stephanie, McDonald, Megan E., Duska, Linda R., Cantuaria, Guilherme, Kavecansky, Juraj, Leath, Charles A., III, Powell, Matthew, Cadungog, Mark G., Rose, Peter G., Kim, Yong-Man, Huang, Helen Q., Provencher, Michèle, Wenzel, Lari B., Bookman, Michael A., Kohn, Elise C., and Secord, Angeles Alvarez

Published
2024
Full Text
View/download PDF

10. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors

Author

Osann, Kathryn, Wenzel, Lari, McKinney, Chelsea, Wagner, Lynne, Cella, David, Fulci, Giulia, Scroggins, Mary J, Lankes, Heather A, Wang, Victoria, Nephew, Kenneth P, Maxwell, George L, Mok, Samuel C, Conrads, Thomas P, Miller, Austin, and Birrer, Michael

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Behavioral and Social Science, Ovarian Cancer, Rare Diseases, Women's Health, Clinical Research, 7.1 Individual care needs, Adult, Humans, Female, Quality of Life, Cancer Survivors, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fear, Ovarian cancer, Long-term survival, Fear of recurrence, Quality of life, Emotional well-being, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveAlthough advanced stage epithelial ovarian cancer is widely considered life-threatening, 17% of women with advanced disease will survive long-term. Little is known about the health-related quality of life (QOL) of long-term ovarian cancer survivors, or how fear of recurrence might affect QOL.Methods58 long-term survivors with advanced disease participated in the study. Participants completed standardized questionnaires to capture cancer history, QOL, and fear of recurrent disease (FOR). Statistical analyses included multivariable linear models.ResultsParticipants averaged 52.8 years at diagnosis and had survived >8 years (mean:13.5); 64% had recurrent disease. Mean FACT-G, FACT-O, and FACT-O-TOI (TOI) scores were 90.7 (SD:11.6), 128.6 (SD:14.8), and 85.9 (SD:10.2) respectively. Compared to the U.S. population using T-scores, QOL for participants exceeded that of healthy adults (T-score (FACT-G) = 55.9). Overall QOL was lower in women with recurrent vs. non-recurrent disease though differences did not reach statistical significance (FACT-O = 126.1 vs. 133.3, p = 0.082). Despite good QOL, high FOR was reported in 27%. FOR was inversely associated with emotional well-being (EWB) (p

Published
2023

11. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

Author

Hakkaart, Christopher, Pearson, John F, Marquart, Louise, Dennis, Joe, Wiggins, George AR, Barnes, Daniel R, Robinson, Bridget A, Mace, Peter D, Aittomäki, Kristiina, Andrulis, Irene L, Arun, Banu K, Azzollini, Jacopo, Balmaña, Judith, Barkardottir, Rosa B, Belhadj, Sami, Berger, Lieke, Blok, Marinus J, Boonen, Susanne E, Borde, Julika, Bradbury, Angela R, Brunet, Joan, Buys, Saundra S, Caligo, Maria A, Campbell, Ian, Chung, Wendy K, Claes, Kathleen BM, Collonge-Rame, Marie-Agnès, Cook, Jackie, Cosgrove, Casey, Couch, Fergus J, Daly, Mary B, Dandiker, Sita, Davidson, Rosemarie, de la Hoya, Miguel, de Putter, Robin, Delnatte, Capucine, Dhawan, Mallika, Diez, Orland, Ding, Yuan Chun, Domchek, Susan M, Donaldson, Alan, Eason, Jacqueline, Easton, Douglas F, Ehrencrona, Hans, Engel, Christoph, Evans, D Gareth, Faust, Ulrike, Feliubadaló, Lidia, Fostira, Florentia, Friedman, Eitan, Frone, Megan, Frost, Debra, Garber, Judy, Gayther, Simon A, Gehrig, Andrea, Gesta, Paul, Godwin, Andrew K, Goldgar, David E, Greene, Mark H, Hahnen, Eric, Hake, Christopher R, Hamann, Ute, Hansen, Thomas VO, Hauke, Jan, Hentschel, Julia, Herold, Natalie, Honisch, Ellen, Hulick, Peter J, Imyanitov, Evgeny N, Isaacs, Claudine, Izatt, Louise, Izquierdo, Angel, Jakubowska, Anna, James, Paul A, Janavicius, Ramunas, John, Esther M, Joseph, Vijai, Karlan, Beth Y, Kemp, Zoe, Kirk, Judy, Konstantopoulou, Irene, Koudijs, Marco, Kwong, Ava, Laitman, Yael, Lalloo, Fiona, Lasset, Christine, Lautrup, Charlotte, Lazaro, Conxi, Legrand, Clémentine, Leslie, Goska, Lesueur, Fabienne, Mai, Phuong L, Manoukian, Siranoush, Mari, Véronique, Martens, John WM, McGuffog, Lesley, Mebirouk, Noura, Meindl, Alfons, Miller, Austin, and Montagna, Marco

Subjects
Human Genome, Prevention, Breast Cancer, Cancer, Genetics, Aetiology, 2.1 Biological and endogenous factors, BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, DNA Copy Number Variations, Female, Genetic Predisposition to Disease, Heterozygote, Humans, RNA, Messenger, GEMO Study Collaborators, EMBRACE Collaborators, SWE-BRCA Investigators, kConFab Investigators, HEBON Investigators
Abstract

The contribution of germline copy number variants (CNVs) to risk of developing cancer in individuals with pathogenic BRCA1 or BRCA2 variants remains relatively unknown. We conducted the largest genome-wide analysis of CNVs in 15,342 BRCA1 and 10,740 BRCA2 pathogenic variant carriers. We used these results to prioritise a candidate breast cancer risk-modifier gene for laboratory analysis and biological validation. Notably, the HR for deletions in BRCA1 suggested an elevated breast cancer risk estimate (hazard ratio (HR) = 1.21), 95% confidence interval (95% CI = 1.09-1.35) compared with non-CNV pathogenic variants. In contrast, deletions overlapping SULT1A1 suggested a decreased breast cancer risk (HR = 0.73, 95% CI 0.59-0.91) in BRCA1 pathogenic variant carriers. Functional analyses of SULT1A1 showed that reduced mRNA expression in pathogenic BRCA1 variant cells was associated with reduced cellular proliferation and reduced DNA damage after treatment with DNA damaging agents. These data provide evidence that deleterious variants in BRCA1 plus SULT1A1 deletions contribute to variable breast cancer risk in BRCA1 carriers.

Published
2022

12. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14

Author

Brown, Jubilee, Miller, Austin, Holman, Laura L., Backes, Floor, Nagel, Christa, Bender, David, Miller, David S., Powell, Matthew A., Westin, Shannon N., Bonebrake, Albert, Muller, Carolyn Y., Secord, Angeles Alvarez, Crane, Erin, Schorge, John, Tew, William P., Sood, Anil K., Bookman, Michael A., Aghajanian, Carol, and Gershenson, David M.

Published
2024
Full Text
View/download PDF

13. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Barretina-Ginesta, Pilar, Bennett, Katherine, Berek, Jonathan, Berger, Regina, Bjørge, Line, Boere, Ingrid, Brennan, Donal, Bruchim, Ilan, Chang, Ting-Chang, Chavez Blanco, Adriana, Chen, Xiaojun, Colombo, Nicoletta, Crosbie, Emma, Denys, Hannelore, Duska, Linda, Fruehauf, Filip, Gomez Garcia, Eva Maria, van Gorp, Toon, Grimm, Christoph, Guitmann, Gustavo, Han, Kathy, Hanker, Lars, Harano, Kenichi, Hasegawa, Kosei, Herrington, C Simon, Ip, Philip, Joly, Florence, Khaw, Pearly, Kohn, Elise, Kristeleit, Rebecca, Kroep, Judith, Leary, Alexandra, Lee, Jung-Yun, Lheureux, Stephanie, Liu, Jihong, Mackay, Helen, Mahner, Sven, Mariani, Andrea, McAlpine, Jessica, Mikami, Yoshiki, Mirza, Mansoor Raza, Mukhopadhyay, Asima, Nagao, Shoji, Ng, Joseph, Nogueira-Rodrigues, Angelica, Novák, Zoltán, O'Donnell, Jennifer, Osborne, Sherill, Perez-Fidalgo, J. Alejandro, Romeo Marin, Margarita, Roy Chowdhury, Rahul, Sadozye, Azmat, Safra, Tamar, Scott, Claire, Sehouli, Jalid, Slomovitz, Brian, Tan, David, Taylor, Alexandra, Valabrega, Giorgio, Veneziani, Ana, Verhoeven, Karen, Vetter, Marcus, Wampfler, Julian, Westin, Shannon, Wimberger, Pauline, Zola, Paolo, Creutzberg, Carien L, Kim, Jae-Weon, Eminowicz, Gemma, Allanson, Emma, Eberst, Lauriane, Kim, Se Ik, Nout, Remi A, Park, Jeong-Yeol, Lorusso, Domenica, Mileshkin, Linda, Ottevanger, Petronella B, Brand, Alison, Mezzanzanica, Delia, Oza, Amit, Gebski, Val, Pothuri, Bhavana, Batley, Tania, Gordon, Carol, Mitra, Tina, White, Helen, Howitt, Brooke, Matias-Guiu, Xavier, Ray-Coquard, Isabelle, Gaffney, David, Small, William, Jr, Miller, Austin, Concin, Nicole, Powell, Matthew A, Stuart, Gavin, and Bookman, Michael A

Published
2024
Full Text
View/download PDF

15. Contributors

Author

Albert, Paul S., primary, Allotey, Prince A., additional, Appleton, Allison A., additional, Attwood, Kristopher, additional, Bergsland, Niels, additional, Bernick, Charles, additional, Chakraborty, Saptarshi, additional, Chen, Zhen, additional, Desai, Gauri, additional, Dodge Francis, Carolee, additional, Dwyer, Michael, additional, Feingold, Beth J., additional, Gao, Xinyu, additional, Harel, Ofer, additional, Holdsworth, Elizabeth A., additional, Hong, Xuan, additional, Kim, Sung Duk, additional, Kordas, Katarzyna, additional, Ledsham, Victoria, additional, Lin, Betty, additional, Liu, Jingxia, additional, Miecznikowski, Jeffrey C., additional, Miller, Austin, additional, Park, Soyun, additional, Shan, Guogen, additional, Sill, Michael, additional, Szapudi, Istvan, additional, Vahter, Marie, additional, Vexler, Albert, additional, Vexler, David, additional, Yu, Jihnhee, additional, Zhou, Jiaojiao, additional, and Zivadinov, Robert, additional

Published
2024
Full Text
View/download PDF

16. WWII remembered

Author

Miller, Austin E., LtCol, Ret

Subjects
WORLD WAR II - Chronology
Abstract

illus

Published
1995

17. WWII remembered

Author

Miller, Austin E., LtCol, Ret

Subjects
WORLD WAR II - Chronology
Abstract

illus

Published
1994

19. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

Author

Gershenson, David M, Miller, Austin, Brady, William E, Paul, James, Carty, Karen, Rodgers, William, Millan, David, Coleman, Robert L, Moore, Kathleen N, Banerjee, Susana, Connolly, Kate, Secord, Angeles Alvarez, O'Malley, David M, Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robert L, Herrington, C Simon, Huang, Helen Q, Wenzel, Lari, and Gourley, Charlie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Ovarian Cancer, Women's Health, 6.1 Pharmaceuticals, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Ovarian Epithelial, Female, Humans, MAP Kinase Kinase 1, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Ovarian Neoplasms, Paclitaxel, Progression-Free Survival, Pyridones, Pyrimidinones, Standard of Care, Treatment Outcome, United Kingdom, United States, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundLow-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma.MethodsThis international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m2 by body surface area once every 4 weeks; intravenous topotecan 4 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, and is active but not recruiting.FindingsBetween Feb 27, 2014, and April 10, 2018, 260 patients were enrolled and randomly assigned to the trametinib group (n=130) or the standard-of-care group (n=130). At the primary analysis, there were 217 progression-free survival events (101 [78%] in the trametinib group and 116 [89%] in the standard-of-care group). Median progression-free survival in the trametinib group was 13·0 months (95% CI 9·9-15·0) compared with 7·2 months (5·6-9·9) in the standard-of-care group (hazard ratio 0·48 [95% CI 0·36-0·64]; p

Published
2022

20. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival

Author

Wenzel, Lari, Osann, Kathryn, McKinney, Chelsea, Cella, David, Fulci, Giulia, Scroggins, Mary J, Lankes, Heather A, Wang, Victoria, Nephew, Kenneth P, Maxwell, George L, Mok, Samuel C, Conrads, Thomas P, Miller, Austin, Mannel, Robert S, Gray, Heidi J, Hanjani, Parviz, Huh, Warner K, Spirtos, Nick, Leitao, Mario M, Glaser, Gretchen, Sharma, Sudarshan K, Santin, Alessandro D, Sperduto, Paul, Lele, Shashikant B, Burger, Robert A, Monk, Bradley J, and Birrer, Michael

Subjects
Cancer, Rehabilitation, Ovarian Cancer, Clinical Research, Rare Diseases, Management of diseases and conditions, 7.1 Individual care needs, Carcinoma, Ovarian Epithelial, Humans, Ovarian Neoplasms, Prognosis, Quality of Life, Survivors, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundThere is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.MethodsQuality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared between long-term survivors (LTS) (8+ years) and short-term survivors (STS) (

Published
2021

21. A Protein-Based Biosensor for Detecting Calcium by Magnetic Resonance Imaging

Author

Ozbakir, Harun F, Miller, Austin DC, Fishman, Kiara B, Martins, André F, Kippin, Tod E, and Mukherjee, Arnab

Subjects
Nutrition, Biomedical Imaging, Bioengineering, Neurosciences, Underpinning research, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 1.1 Normal biological development and functioning, Generic health relevance, Animals, Biosensing Techniques, CHO Cells, Calcium, Cricetinae, Cricetulus, Magnetic Resonance Imaging, magnetic resonance imaging, calcium imaging, genetically encoded reporters, neuroimaging, Mn2+ enhanced MRI, Analytical Chemistry, Biomedical Engineering, Nanotechnology
Abstract

Calcium-responsive contrast agents for magnetic resonance imaging (MRI) offer a promising approach for noninvasive brain-wide monitoring of neural activity at any arbitrary depth. Current examples of MRI-based calcium probes involve synthetic molecules and nanoparticles, which cannot be used to examine calcium signaling in a genetically encoded form. Here, we describe a new MRI sensor for calcium, based entirely on a naturally occurring calcium-binding protein known as calprotectin. Calcium-binding causes calprotectin to sequester manganese ions, thereby limiting Mn2+ enhanced paramagnetic relaxation of nearby water molecules. We demonstrate that this mechanism allows calprotectin to alter T1 and T2 based MRI signals in response to biologically relevant calcium concentrations. The resulting response amplitude, i.e., change in relaxation time, is comparable to existing MRI-based calcium sensors as well as other reported protein-based MRI sensors. As a preliminary demonstration of its biological applicability, we used calprotectin to detect calcium in a lysed hippocampal cell preparation as well as in intact Chinese hamster ovary cells treated with a calcium ionophore. Calprotectin thus represents a promising path toward noninvasive imaging of calcium signaling by combining the molecular and cellular specificity of genetically encodable tools with the ability of MRI to image through scattering tissue of any size and depth.

Published
2021

22. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.

Author

Lakeman, Inge MM, van den Broek, Alexandra J, Vos, Juliën AM, Barnes, Daniel R, Adlard, Julian, Andrulis, Irene L, Arason, Adalgeir, Arnold, Norbert, Arun, Banu K, Balmaña, Judith, Barrowdale, Daniel, Benitez, Javier, Borg, Ake, Caldés, Trinidad, Caligo, Maria A, Chung, Wendy K, Claes, Kathleen BM, GEMO Study Collaborators, EMBRACE Collaborators, Collée, J Margriet, Couch, Fergus J, Daly, Mary B, Dennis, Joe, Dhawan, Mallika, Domchek, Susan M, Eeles, Ros, Engel, Christoph, Evans, D Gareth, Feliubadaló, Lidia, Foretova, Lenka, Friedman, Eitan, Frost, Debra, Ganz, Patricia A, Garber, Judy, Gayther, Simon A, Gerdes, Anne-Marie, Godwin, Andrew K, Goldgar, David E, Hahnen, Eric, Hake, Christopher R, Hamann, Ute, Hogervorst, Frans BL, Hooning, Maartje J, Hopper, John L, Hulick, Peter J, Imyanitov, Evgeny N, OCGN Investigators, HEBON Investigators, KconFab Investigators, Isaacs, Claudine, Izatt, Louise, Jakubowska, Anna, James, Paul A, Janavicius, Ramunas, Jensen, Uffe Birk, Jiao, Yue, John, Esther M, Joseph, Vijai, Karlan, Beth Y, Kets, Carolien M, Konstantopoulou, Irene, Kwong, Ava, Legrand, Clémentine, Leslie, Goska, Lesueur, Fabienne, Loud, Jennifer T, Lubiński, Jan, Manoukian, Siranoush, McGuffog, Lesley, Miller, Austin, Gomes, Denise Molina, Montagna, Marco, Mouret-Fourme, Emmanuelle, Nathanson, Katherine L, Neuhausen, Susan L, Nevanlinna, Heli, Yie, Joanne Ngeow Yuen, Olah, Edith, Olopade, Olufunmilayo I, Park, Sue K, Parsons, Michael T, Peterlongo, Paolo, Piedmonte, Marion, Radice, Paolo, Rantala, Johanna, Rennert, Gad, Risch, Harvey A, Schmutzler, Rita K, Sharma, Priyanka, Simard, Jacques, Singer, Christian F, Stadler, Zsofia, Stoppa-Lyonnet, Dominique, Sutter, Christian, Tan, Yen Yen, Teixeira, Manuel R, Teo, Soo Hwang, Teulé, Alex, Thomassen, Mads, and Thull, Darcy L

Subjects
GEMO Study Collaborators, EMBRACE Collaborators, OCGN Investigators, HEBON Investigators, KconFab Investigators, Humans, Breast Neoplasms, Genetic Predisposition to Disease, BRCA1 Protein, BRCA2 Protein, Risk Factors, Retrospective Studies, Heterozygote, Mutation, Adult, Female, Prevention, Cancer, Aging, Breast Cancer, 2.1 Biological and endogenous factors, Genetics & Heredity, Genetics, Clinical Sciences
Abstract

PurposeTo evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes.MethodsWe included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk.ResultsFor BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06-1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07-1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC

Published
2021

23. World War II remembered, May 1944

Author

Miller, Austin E., LtCol, Ret

Subjects
WORLD WAR II - Campaigns and Battles, WORLD WAR II - Chronology
Abstract

illus

Published
1994

24. Calcium-responsive contrast agents for functional magnetic resonance imaging

Author

Miller, Austin DC, Ozbakir, Harun F, and Mukherjee, Arnab

Subjects
Biomedical and Clinical Sciences, Engineering, Biomedical Engineering, Biomedical Imaging, Bioengineering, Nanotechnology, Neurosciences, Neurological
Abstract

Calcium ions represent one of the key second messengers accompanying neural activity and synaptic signaling. Accordingly, dynamic imaging of calcium fluctuations in living organisms represents a cornerstone technology for discovering neural mechanisms that underlie memory, determine behavior, and modulate emotional states as well as how these mechanisms are perturbed by neurological disease and brain injury. While optical technologies are well established for high resolution imaging of calcium dynamics, physical limits on light penetration hinder their application for whole-brain imaging in intact vertebrates. Unlike optics, magnetic resonance imaging (MRI) enables noninvasive large-scale imaging across vertebrates of all sizes. This has motivated the development of several sensors that leverage innovative physicochemical mechanisms to sensitize MRI contrast to intracellular and extracellular changes in calcium. Here, we review the current state-of-the-art in MRI-based calcium sensors, focusing on fundamental aspects of sensor performance, in vivo applications, and challenges related to sensitivity. We also highlight how innovations at the intersection of reporter gene technology and gene delivery open potential opportunities for mapping calcium activity in genetically targeted cells, complementing the benefits of small molecule probes and nanoparticle sensors.

Published
2021

25. Autonomous Industrial Assembly using Force, Torque, and RGB-D sensing

Author

Watson, James, Miller, Austin, and Correll, Nikolaus

Subjects
Computer Science - Robotics
Abstract

We present algorithms and results for a robotic manipulation system that was designed to be easily programmable and adaptable to various tasks common to industrial setting, which is inspired by the Industrial Assembly Challenge at the 2018 World Robotics Summit in Tokyo. This challenge included assembly of standard, commercially available industrial parts into 2D and 3D assemblies. We demonstrate three tasks that can be classified into "peg-in-hole" and "hole-on-peg" tasks and identify two canonical algorithms: spiral-based search and tilting insertion. Both algorithms use hand-coded thresholds in the force and torque domains to detect critical points in the assembly. After briefly summarizing the state of the art in research, we describe the strategy and approach utilized by the tested system, how it's design bears on its performance, statistics on 20 experimental trials for each task, lessons learned during the development of the system, and open research challenges that still remain.

Published
2020
Full Text
View/download PDF

26. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Author

Pignata, Sandro, Bookman, Michael, Sehouli, Jalid, Miller, Austin, Penson, Richard T., Taskiran, Cagatay, Anderson, Charles, Hietanen, Sakari, Myers, Tashanna, Madry, Radoslaw, Willmott, Lyndsay, Lortholary, Alain, Thomes-Pepin, Jessica, Aghajanian, Carol, McCourt, Carolyn, Stuckey, Ashley, Wu, Xiaohua, Nishio, Shin, Copeland, Larry J., He, Yvette, Molinero, Luciana, Patel, Sheetal, Lin, Yvonne G., Khor, Victor K., and Moore, Kathleen N.

Published
2023
Full Text
View/download PDF

27. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283

Author

O'Cearbhaill, Roisin E., Miller, Austin, Soslow, Robert A., Lankes, Heather A., DeLair, Deborah, Segura, Sheila, Chavan, Shweta, Zamarin, Dmitriy, DeBernardo, Robert, Moore, Kathleen, Moroney, John, Shahin, Mark, Thaker, Premal H., Wahner-Hendrickson, Andrea E., and Aghajanian, Carol

Published
2023
Full Text
View/download PDF

28. Woman who fatally shot Black neighbor gets 25-year sentence

Author

Miller, Austin L.

Subjects
Company legal issue, Shooting -- Cases, Murder -- Cases
Abstract

Byline: Austin L. Miller, Ocala Star-Banner, USA TODAY NETWORK A white Florida woman who fatally shot a Black neighbor through a closed door was sentenced this week to 25 years [...]

Published
2024

30. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

Author

Praiss, Aaron M., Miller, Austin, Smith, Judith, Lichtman, Stuart M., Bookman, Michael, Aghajanian, Carol, Sabbatini, Paul, Backes, Floor, Cohn, David E., Argenta, Peter, Friedlander, Michael, Goodheart, Michael J., Mutch, David G., Gershenson, David M., Tewari, Krishnansu S., Wenham, Robert M., Wahner Hendrickson, Andrea E., Lee, Roger B., Gray, Heidi, Secord, Angeles Alvarez, Van Le, Linda, and O'Cearbhaill, Roisin E.

Published
2023
Full Text
View/download PDF

32. Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Author

Thomson, Cynthia A., Crane, Tracy E., Miller, Austin, Gold, Michael A., Powell, Matthew, Bixel, Kristin, Van Le, Linda, DiSilvestro, Paul, Ratner, Elena, Lele, Shashikant, Guntupalli, Saketh, Huh, Warner, Robertson, Sharon E., Modesitt, Susan, Casey, A. Catherine, Basen-Engquist, Karen, Skiba, Meghan, Walker, Joan, Kachnic, Lisa, and Alberts, David S.

Published
2023
Full Text
View/download PDF

33. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

Author

Qian, Frank, Rookus, Matti A, Leslie, Goska, Risch, Harvey A, Greene, Mark H, Aalfs, Cora M, Adank, Muriel A, Adlard, Julian, Agnarsson, Bjarni A, Ahmed, Munaza, Aittomäki, Kristiina, Andrulis, Irene L, Arnold, Norbert, Arun, Banu K, Ausems, Margreet GEM, Azzollini, Jacopo, Barrowdale, Daniel, Barwell, Julian, Benitez, Javier, Białkowska, Katarzyna, Bonadona, Valérie, Borde, Julika, Borg, Ake, Bradbury, Angela R, Brunet, Joan, Buys, Saundra S, Caldés, Trinidad, Caligo, Maria A, Campbell, Ian, Carter, Jonathan, Chiquette, Jocelyne, Chung, Wendy K, Claes, Kathleen BM, Collée, J Margriet, Collonge-Rame, Marie-Agnès, Couch, Fergus J, Daly, Mary B, Delnatte, Capucine, Diez, Orland, Domchek, Susan M, Dorfling, Cecilia M, Eason, Jacqueline, Easton, Douglas F, Eeles, Ros, Engel, Christoph, Evans, D Gareth, Faivre, Laurence, Feliubadaló, Lidia, Foretova, Lenka, Friedman, Eitan, Frost, Debra, Ganz, Patricia A, Garber, Judy, Garcia-Barberan, Vanesa, Gehrig, Andrea, Glendon, Gord, Godwin, Andrew K, Gómez Garcia, Encarna B, Hamann, Ute, Hauke, Jan, Hopper, John L, Hulick, Peter J, Imyanitov, Evgeny N, Isaacs, Claudine, Izatt, Louise, Jakubowska, Anna, Janavicius, Ramunas, John, Esther M, Karlan, Beth Y, Kets, Carolien M, Laitman, Yael, Lázaro, Conxi, Leroux, Dominique, Lester, Jenny, Lesueur, Fabienne, Loud, Jennifer T, Lubiński, Jan, Łukomska, Alicja, McGuffog, Lesley, Mebirouk, Noura, Meijers-Heijboer, Hanne EJ, Meindl, Alfons, Miller, Austin, Montagna, Marco, Mooij, Thea M, Mouret-Fourme, Emmanuelle, Nathanson, Katherine L, Nehoray, Bita, Neuhausen, Susan L, Nevanlinna, Heli, Nielsen, Finn C, Offit, Kenneth, Olah, Edith, Ong, Kai-ren, Oosterwijk, Jan C, Ottini, Laura, Parsons, Michael T, Peterlongo, Paolo, Pfeiler, Georg, and Pradhan, Nisha

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Genetics, Rare Diseases, Women's Health, Ovarian Cancer, Nutrition, Cancer, Obesity, Breast Cancer, Aging, Genetic Testing, 2.1 Biological and endogenous factors, Adult, Aged, Body Height, Body Mass Index, Female, Genes, BRCA1, Genes, BRCA2, Heterozygote, Humans, Mendelian Randomization Analysis, Menopause, Middle Aged, Mutation, Ovarian Neoplasms, Proportional Hazards Models, KConFab Investigators, HEBON Investigators, GEMO Study Collaborators, EMBRACE Collaborators, CIMBA, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundHeight and body mass index (BMI) are associated with higher ovarian cancer risk in the general population, but whether such associations exist among BRCA1/2 mutation carriers is unknown.MethodsWe applied a Mendelian randomisation approach to examine height/BMI with ovarian cancer risk using the Consortium of Investigators for the Modifiers of BRCA1/2 (CIMBA) data set, comprising 14,676 BRCA1 and 7912 BRCA2 mutation carriers, with 2923 ovarian cancer cases. We created a height genetic score (height-GS) using 586 height-associated variants and a BMI genetic score (BMI-GS) using 93 BMI-associated variants. Associations were assessed using weighted Cox models.ResultsObserved height was not associated with ovarian cancer risk (hazard ratio [HR]: 1.07 per 10-cm increase in height, 95% confidence interval [CI]: 0.94-1.23). Height-GS showed similar results (HR = 1.02, 95% CI: 0.85-1.23). Higher BMI was significantly associated with increased risk in premenopausal women with HR = 1.25 (95% CI: 1.06-1.48) and HR = 1.59 (95% CI: 1.08-2.33) per 5-kg/m2 increase in observed and genetically determined BMI, respectively. No association was found for postmenopausal women. Interaction between menopausal status and BMI was significant (Pinteraction

Published
2019

34. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Author

Qian, Frank, Wang, Shengfeng, Mitchell, Jonathan, McGuffog, Lesley, Barrowdale, Daniel, Leslie, Goska, Oosterwijk, Jan C, Chung, Wendy K, Evans, D Gareth, Engel, Christoph, Kast, Karin, Aalfs, Cora M, Adank, Muriel A, Adlard, Julian, Agnarsson, Bjarni A, Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L, Arun, Banu K, Ausems, Margreet GEM, Azzollini, Jacopo, Barouk-Simonet, Emmanuelle, Barwell, Julian, Belotti, Muriel, Benitez, Javier, Berger, Andreas, Borg, Ake, Bradbury, Angela R, Brunet, Joan, Buys, Saundra S, Caldes, Trinidad, Caligo, Maria A, Campbell, Ian, Caputo, Sandrine M, Chiquette, Jocelyne, Claes, Kathleen BM, Margriet Collée, J, Couch, Fergus J, Coupier, Isabelle, Daly, Mary B, Davidson, Rosemarie, Diez, Orland, Domchek, Susan M, Donaldson, Alan, Dorfling, Cecilia M, Eeles, Ros, Feliubadaló, Lidia, Foretova, Lenka, Fowler, Jeffrey, Friedman, Eitan, Frost, Debra, Ganz, Patricia A, Garber, Judy, Garcia-Barberan, Vanesa, Glendon, Gord, Godwin, Andrew K, Gómez Garcia, Encarna B, Gronwald, Jacek, Hahnen, Eric, Hamann, Ute, Henderson, Alex, Hendricks, Carolyn B, Hopper, John L, Hulick, Peter J, Imyanitov, Evgeny N, Isaacs, Claudine, Izatt, Louise, Izquierdo, Ángel, Jakubowska, Anna, Kaczmarek, Katarzyna, Kang, Eunyoung, Karlan, Beth Y, Kets, Carolien M, Kim, Sung-Won, Kim, Zisun, Kwong, Ava, Laitman, Yael, Lasset, Christine, Hyuk Lee, Min, Won Lee, Jong, Lee, Jihyoun, Lester, Jenny, Lesueur, Fabienne, Loud, Jennifer T, Lubinski, Jan, Mebirouk, Noura, Meijers-Heijboer, Hanne EJ, Meindl, Alfons, Miller, Austin, Montagna, Marco, Mooij, Thea M, Morrison, Patrick J, Mouret-Fourme, Emmanuelle, Nathanson, Katherine L, Neuhausen, Susan L, Nevanlinna, Heli, Niederacher, Dieter, Nielsen, Finn C, Nussbaum, Robert L, and Offit, Kenneth

Subjects
GEMO Study Collaborators, HEBON, EMBRACE, Humans, Breast Neoplasms, Genetic Predisposition to Disease, BRCA1 Protein, BRCA2 Protein, Body Mass Index, Body Height, Prognosis, Risk Factors, Mutation, Polymorphism, Single Nucleotide, Adult, Female, Mendelian Randomization Analysis, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

BackgroundBRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers remains unclear.MethodsWe used Mendelian randomization approaches to evaluate the association of height and BMI on breast cancer risk, using data from the Consortium of Investigators of Modifiers of BRCA1/2 with 14 676 BRCA1 and 7912 BRCA2 mutation carriers, including 11 451 cases of breast cancer. We created a height genetic score using 586 height-associated variants and a BMI genetic score using 93 BMI-associated variants. We examined both observed and genetically determined height and BMI with breast cancer risk using weighted Cox models. All statistical tests were two-sided.ResultsObserved height was positively associated with breast cancer risk (HR = 1.09 per 10 cm increase, 95% confidence interval [CI] = 1.0 to 1.17; P = 1.17). Height genetic score was positively associated with breast cancer, although this was not statistically significant (per 10 cm increase in genetically predicted height, HR = 1.04, 95% CI = 0.93 to 1.17; P = .47). Observed BMI was inversely associated with breast cancer risk (per 5 kg/m2 increase, HR = 0.94, 95% CI = 0.90 to 0.98; P = .007). BMI genetic score was also inversely associated with breast cancer risk (per 5 kg/m2 increase in genetically predicted BMI, HR = 0.87, 95% CI = 0.76 to 0.98; P = .02). BMI was primarily associated with premenopausal breast cancer.ConclusionHeight is associated with overall breast cancer and BMI is associated with premenopausal breast cancer in BRCA1/2 mutation carriers. Incorporating height and BMI, particularly genetic score, into risk assessment may improve cancer management.

Published
2019

35. White woman guilty in shooting of Black neighbor

Author

Miller, Austin L. and Star-Banner, Ocala

Subjects
Manslaughter -- Cases, Company legal issue, News, opinion and commentary
Abstract

Byline: Austin L. Miller, Ocala Star-Banner, USA TODAY OCALA, Fla. - A white woman who fatally shot her Black neighbor through a locked door amid a neighborhood feud in Florida [...]

Published
2024

36. Engineering water exchange is a safe and effective method for magnetic resonance imaging in diverse cell types

Author

Miller, Austin DC, Miller, Austin DC, Chowdhury, Soham P, Hanson, Hadley W, Linderman, Sarah K, Ghasemi, Hannah I, Miller, Wyatt D, Morrissey, Meghan A, Richardson, Chris D, Gardner, Brooke M, Mukherjee, Arnab, Miller, Austin DC, Miller, Austin DC, Chowdhury, Soham P, Hanson, Hadley W, Linderman, Sarah K, Ghasemi, Hannah I, Miller, Wyatt D, Morrissey, Meghan A, Richardson, Chris D, Gardner, Brooke M, and Mukherjee, Arnab

Abstract

Aquaporin-1 (Aqp1), a water channel, has garnered significant interest for cell-based medicine and in vivo synthetic biology due to its ability to be genetically encoded to produce magnetic resonance signals by increasing the rate of water diffusion in cells. However, concerns regarding the effects of Aqp1 overexpression and increased membrane diffusivity on cell physiology have limited its widespread use as a deep-tissue reporter. In this study, we present evidence that Aqp1 generates strong diffusion-based magnetic resonance signals without adversely affecting cell viability or morphology in diverse cell lines derived from mice and humans. Our findings indicate that Aqp1 overexpression does not induce ER stress, which is frequently associated with heterologous expression of membrane proteins. Furthermore, we observed that Aqp1 expression had no detrimental effects on native biological activities, such as phagocytosis, immune response, insulin secretion, and tumor cell migration in the analyzed cell lines. These findings should serve to alleviate any lingering safety concerns regarding the utilization of Aqp1 as a genetic reporter and should foster its broader application as a noninvasive reporter for in vivo studies.

Published
2024

38. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Author

Dareng, Eileen O., Tyrer, Jonathan P., Barnes, Daniel R., Jones, Michelle R., Yang, Xin, Aben, Katja K. H., Adank, Muriel A., Agata, Simona, Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Aravantinos, Gerasimos, Arun, Banu K., Augustinsson, Annelie, Balmaña, Judith, Bandera, Elisa V., Barkardottir, Rosa B., Barrowdale, Daniel, Beckmann, Matthias W., Beeghly-Fadiel, Alicia, Benitez, Javier, Bermisheva, Marina, Bernardini, Marcus Q., Bjorge, Line, Black, Amanda, Bogdanova, Natalia V., Bonanni, Bernardo, Borg, Ake, Brenton, James D., Budzilowska, Agnieszka, Butzow, Ralf, Buys, Saundra S., Cai, Hui, Caligo, Maria A., Campbell, Ian, Cannioto, Rikki, Cassingham, Hayley, Chang-Claude, Jenny, Chanock, Stephen J., Chen, Kexin, Chiew, Yoke-Eng, Chung, Wendy K., Claes, Kathleen B. M., Colonna, Sarah, Cook, Linda S., Couch, Fergus J., Daly, Mary B., Dao, Fanny, Davies, Eleanor, de la Hoya, Miguel, de Putter, Robin, Dennis, Joe, DePersia, Allison, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Doherty, Jennifer A., Domchek, Susan M., Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana M., Eliassen, Heather A., Engel, Christoph, Evans, Gareth D., Fasching, Peter A., Flanagan, James M., Fortner, Renée T., Machackova, Eva, Friedman, Eitan, Ganz, Patricia A., Garber, Judy, Gensini, Francesca, Giles, Graham G., Glendon, Gord, Godwin, Andrew K., Goodman, Marc T., Greene, Mark H., Gronwald, Jacek, Hahnen, Eric, Haiman, Christopher A., Håkansson, Niclas, Hamann, Ute, Hansen, Thomas V. O., Harris, Holly R., Hartman, Mikael, Heitz, Florian, Hildebrandt, Michelle A. T., Høgdall, Estrid, Høgdall, Claus K., Hopper, John L., Huang, Ruea-Yea, Huff, Chad, Hulick, Peter J., Huntsman, David G., Imyanitov, Evgeny N., Isaacs, Claudine, Jakubowska, Anna, James, Paul A., Janavicius, Ramunas, Jensen, Allan, Johannsson, Oskar Th., John, Esther M., Jones, Michael E., Kang, Daehee, Karlan, Beth Y., Karnezis, Anthony, Kelemen, Linda E., Khusnutdinova, Elza, Kiemeney, Lambertus A., Kim, Byoung-Gie, Kjaer, Susanne K., Komenaka, Ian, Kupryjanczyk, Jolanta, Kurian, Allison W., Kwong, Ava, Lambrechts, Diether, Larson, Melissa C., Lazaro, Conxi, Le, Nhu D., Leslie, Goska, Lester, Jenny, Lesueur, Fabienne, Levine, Douglas A., Li, Lian, Li, Jingmei, Loud, Jennifer T., Lu, Karen H., Lubiński, Jan, Mai, Phuong L., Manoukian, Siranoush, Marks, Jeffrey R., Matsuno, Rayna Kim, Matsuo, Keitaro, May, Taymaa, McGuffog, Lesley, McLaughlin, John R., McNeish, Iain A., Mebirouk, Noura, Menon, Usha, Miller, Austin, Milne, Roger L., Minlikeeva, Albina, Modugno, Francesmary, Montagna, Marco, Moysich, Kirsten B., Munro, Elizabeth, Nathanson, Katherine L., Neuhausen, Susan L., Nevanlinna, Heli, Yie, Joanne Ngeow Yuen, Nielsen, Henriette Roed, Nielsen, Finn C., Nikitina-Zake, Liene, Odunsi, Kunle, Offit, Kenneth, Olah, Edith, Olbrecht, Siel, Olopade, Olufunmilayo I., Olson, Sara H., Olsson, Håkan, Osorio, Ana, Papi, Laura, Park, Sue K., Parsons, Michael T., Pathak, Harsha, Pedersen, Inge Sokilde, Peixoto, Ana, Pejovic, Tanja, Perez-Segura, Pedro, Permuth, Jennifer B., Peshkin, Beth, Peterlongo, Paolo, Piskorz, Anna, Prokofyeva, Darya, Radice, Paolo, Rantala, Johanna, Riggan, Marjorie J., Risch, Harvey A., Rodriguez-Antona, Cristina, Ross, Eric, Rossing, Mary Anne, Runnebaum, Ingo, Sandler, Dale P., Santamariña, Marta, Soucy, Penny, Schmutzler, Rita K., Setiawan, V. Wendy, Shan, Kang, Sieh, Weiva, Simard, Jacques, Singer, Christian F., Sokolenko, Anna P., Song, Honglin, Southey, Melissa C., Steed, Helen, Stoppa-Lyonnet, Dominique, Sutphen, Rebecca, Swerdlow, Anthony J., Tan, Yen Yen, Teixeira, Manuel R., Teo, Soo Hwang, Terry, Kathryn L., Terry, Mary Beth, Thomassen, Mads, Thompson, Pamela J., Thomsen, Liv Cecilie Vestrheim, Thull, Darcy L., Tischkowitz, Marc, Titus, Linda, Toland, Amanda E., Torres, Diana, Trabert, Britton, Travis, Ruth, Tung, Nadine, Tworoger, Shelley S., Valen, Ellen, van Altena, Anne M., van der Hout, Annemieke H., Van Nieuwenhuysen, Els, van Rensburg, Elizabeth J., Vega, Ana, Edwards, Digna Velez, Vierkant, Robert A., Wang, Frances, Wappenschmidt, Barbara, Webb, Penelope M., Weinberg, Clarice R., Weitzel, Jeffrey N., Wentzensen, Nicolas, White, Emily, Whittemore, Alice S., Winham, Stacey J., Wolk, Alicja, Woo, Yin-Ling, Wu, Anna H., Yan, Li, Yannoukakos, Drakoulis, Zavaglia, Katia M., Zheng, Wei, Ziogas, Argyrios, Zorn, Kristin K., Kleibl, Zdenek, Easton, Douglas, Lawrenson, Kate, DeFazio, Anna, Sellers, Thomas A., Ramus, Susan J., Pearce, Celeste L., Monteiro, Alvaro N., Cunningham, Julie, Goode, Ellen L., Schildkraut, Joellen M., Berchuck, Andrew, Chenevix-Trench, Georgia, Gayther, Simon A., Antoniou, Antonis C., and Pharoah, Paul D. P.

Published
2022
Full Text
View/download PDF

39. Front Cover

Author

Miller, Austin B., primary, Frank, Ethan, additional, Simental, Alfred A., additional, and Feng, Max, additional

Published
2024
Full Text
View/download PDF

40. White woman convicted of manslaughter in fatal shooting of Black neighbor

Author

Miller, Austin L.

Subjects
Manslaughter, News, opinion and commentary, Sports and fitness
Abstract

Byline: Austin L. Miller Ocala Star-Banner Show Caption Hide Caption Video from Day 3 of the Susan Lorincz manslaughter trial in Ocala, FloridaSusan Lorincz is charged with manslaughter with a [...]

Published
2024

42. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Author

Horowitz, Neil, Larry Maxwell, G, Miller, Austin, Hamilton, Chad, Rungruang, Bunja, Rodriguez, Noah, Richard, Scott, Krivak, Thomas, Fowler, Jeffrey, Mutch, David, Van Le, Linda, Lee, Roger, Argenta, Peter, Bender, David, Gershenson, David, Java, James, Bookman, Michael, and Tewari, Krishnansu

Subjects
Microscopic residual, Ovarian cancer, Aged, CA-125 Antigen, Carcinoma, Ovarian Epithelial, Cohort Studies, Cytoreduction Surgical Procedures, Female, Humans, Membrane Proteins, Middle Aged, Models, Statistical, Neoplasm Staging, Neoplasm, Residual, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Predictive Value of Tests, Randomized Controlled Trials as Topic, Regression Analysis
Abstract

OBJECTIVE: Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. METHODS: Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these variables were subsequently analyzed using multivariable regression. The regression model was reduced using backward selection and predictive accuracy was quantified using area under the receiver operating characteristic area under the curve (AUC) in both the training and the validation data sets. RESULTS: Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis. The training data set consisted of 1007 patients (234 with R0) while the validation set was comprised of 473 patients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of R0 at cytoreduction: Disease Score (DS) (p

Published
2018

44. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Author

Rungruang, Bunja, Miller, Austin, Krivak, Thomas, Horowitz, Neil, Rodriguez, Noah, Hamilton, Chad, Backes, Floor, Carson, Linda, Friedlander, Michael, Mutch, David, Goodheart, Michael, Wenham, Robert, Bookman, Michael, Maxwell, G, Richard, Scott, and Tewari, Krishnansu

Subjects
disease burden, lymphadenectomy, ovarian cancer, retroperitoneal exploration, surgical debulking, Adult, Aged, Aged, 80 and over, Carcinoma, Ovarian Epithelial, Cytoreduction Surgical Procedures, Female, Humans, Lymph Nodes, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Odds Ratio, Ovarian Neoplasms, Retroperitoneal Space, Survival Analysis, Treatment Outcome
Abstract

BACKGROUND: The purpose of this study was to determine the effect of retroperitoneal (RP) exploration on progression-free survival (PFS) and overall survival (OS) in epithelial ovarian cancer (EOC) patients with stage IIIC disease who underwent optimal debulking surgery. METHODS: Data were collected from records of the Gynecologic Oncology Group 182 (GOG-182) study of stage IIIC EOC patients cytoreduced to no gross residual disease (R0) or minimal gross residual ( 2 cm IP tumor without lymph node involvement (IP/RP-), 2) > 2 cm IP tumor with lymph node involvement (IP/RP+), and 3) > 2 cm IP tumor with no RP exploration (IP/RP?). The effects of disease distribution and RP exploration on PFS and OS were assessed using Kaplan-Meier and proportional hazards methods. RESULTS: There were 1871 stage IIIC patients in GOG-182 who underwent optimal primary debulking surgery. Of these, 689 (36.8%) underwent RP exploration with removal of lymph nodes from at least 1 para-aortic site, and 1182 (63.2%) did not. There were 269 patients in the IP/RP- group, 420 patients in the IP/RP + group, and 1182 patients in the IP/RP? group. Improved PFS (18.5 vs 16.0 months; P

Published
2017

45. Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer

Author

Arend, Rebecca C., Monk, Bradley J., Herzog, Thomas J., Moore, Kathleen N., Shapira-Frommer, Ronnie, Ledermann, Jonathan A., Tewari, Krishnansu S., Secord, Angeles Alvarez, Rachmilewitz Minei, Tamar, Freedman, Laurence S., Miller, Austin, Shmueli, Shifra Fain, Lavi, Michal, and Penson, Richard T.

Published
2021
Full Text
View/download PDF

48. Blast-related mild TBI: LIMBIC-CENC focused review with implications commentary.

Author

Miller, Austin R., Martindale, Sarah L., Rowland, Jared A., Walton, Samuel, Talmy, Tomer, and Walker, William C.

Subjects
*BRAIN anatomy, *INJURY complications, *MEDICAL care use, *MENTAL health, *CLINICAL medicine research, *WEAPONS, *BRAIN, *HEADACHE, *SEVERITY of illness index, *TREATMENT effectiveness, *BRAIN injuries, *BLAST injuries, *CONSORTIA, *NEURORADIOLOGY, *MILITARY personnel, *ACTIVITIES of daily living, *DISEASE risk factors, *DISEASE complications
Abstract

BACKGROUND: A significant factor for the high prevalence of traumatic brain injury (TBI) among U.S. service members is their exposure to explosive munitions leading to blast-related TBI. Our understanding of the specific clinical effects of mild TBI having a component of blast mechanism remains limited compared to pure blunt mechanisms. OBJECTIVE: The purpose of this review is to provide a synopsis of clinical research findings on the long-term effects of blast-related mild TBI derived to date from the Long-Term Impact of Military-Relevant Brain Injury Consortium - Chronic Effects of Neurotrauma Consortium (LIMBIC-CENC). METHODS: Publications on blast-related mild TBI from LIMBIC-CENC and the LIMBIC-CENC prospective longitudinal study (PLS) cohort were reviewed and their findings summarized. Findings from the broader literature on blast-related mild TBI that evaluate similar outcomes are additionally reviewed for a perspective on the state of the literature. RESULTS: The most consistent and compelling evidence for long-term effects of blast-related TBI is for poorer psychological health, greater healthcare utilization and disability levels, neuroimaging impacts on brain structure and function, and greater headache impact on daily life. To date, evidence for chronic cognitive performance deficits from blast-related mild TBI is limited, but futher research including crucial longitudinal data is needed. CONCLUSION: Commentary is provided on: how LIMBIC-CENC findings assimilate with the broader literature; ongoing research gaps alongside future research needs and priorities; how the scientific community can utilize the LIMBIC-CENC database for independent or collaborative research; and how the evidence from the clinical research should be assimilated into clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Author

Barnes, Daniel R., Rookus, Matti A., McGuffog, Lesley, Leslie, Goska, Mooij, Thea M., Dennis, Joe, Mavaddat, Nasim, Adlard, Julian, Ahmed, Munaza, Aittomäki, Kristiina, Andrieu, Nadine, Andrulis, Irene L., Arnold, Norbert, Arun, Banu K., Azzollini, Jacopo, Balmaña, Judith, Barkardottir, Rosa B., Barrowdale, Daniel, Benitez, Javier, Berthet, Pascaline, Białkowska, Katarzyna, Blanco, Amie M., Blok, Marinus J., Bonanni, Bernardo, Boonen, Susanne E., Borg, Åke, Bozsik, Aniko, Bradbury, Angela R., Brennan, Paul, Brewer, Carole, Brunet, Joan, Buys, Saundra S., Caldés, Trinidad, Caligo, Maria A., Campbell, Ian, Christensen, Lise Lotte, Chung, Wendy K., Claes, Kathleen B.M., Colas, Chrystelle, Collonge-Rame, Marie-Agnès, Delnatte, Capucine, Faivre, Laurence, Giraud, Sophie, Lasset, Christine, Mari, Véronique, Mebirouk, Noura, Mouret-Fourme, Emmanuelle, Schuster, Hélène, Stoppa-Lyonnet, Dominique, Antoniou, Antonis, Cook, Jackie, Davidson, Rosemarie, Easton, Douglas, Eeles, Ros, Evans, D. Gareth, Frost, Debra, Hanson, Helen, Izatt, Louise, Ong, Kai-ren, Side, Lucy, O’Shaughnessy-Kirwan, Aoife, Tischkowitz, Marc, Walker, Lisa, Daly, Mary B., de la Hoya, Miguel, de Putter, Robin, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Domchek, Susan M., Dorfling, Cecilia M., Dumont, Martine, Ejlertsen, Bent, Engel, Christoph, Foretova, Lenka, Fostira, Florentia, Friedlander, Michael, Friedman, Eitan, Ganz, Patricia A., Garber, Judy, Gehrig, Andrea, Gerdes, Anne-Marie, Gesta, Paul, Glendon, Gord, Godwin, Andrew K., Goldgar, David E., González-Neira, Anna, Greene, Mark H., Gschwantler-Kaulich, Daphne, Hahnen, Eric, Hamann, Ute, Hentschel, Julia, Hogervorst, Frans B.L., Hooning, Maartje J., Horvath, Judit, Hu, Chunling, Hulick, Peter J., Imyanitov, Evgeny N., Chenevix-Trench, Georgia, Phillips, Kelly-Anne, Spurdle, Amanda, Blok, Marinus, Hogervorst, Frans, Hooning, Maartje, Koudijs, Marco, Mensenkamp, Arjen, Meijers-Heijboer, Hanne, Rookus, Matti, Engelen, Klaartje van, Noguès, Catherine, Isaacs, Claudine, Izquierdo, Angel, Jakubowska, Anna, James, Paul A., Janavicius, Ramunas, John, Esther M., Joseph, Vijai, Karlan, Beth Y., Kast, Karin, Kruse, Torben A., Kwong, Ava, Laitman, Yael, Lazaro, Conxi, Lester, Jenny, Lesueur, Fabienne, Liljegren, Annelie, Loud, Jennifer T., Lubiński, Jan, Mai, Phuong L., Manoukian, Siranoush, Meijers-Heijboer, Hanne E.J., Meindl, Alfons, Mensenkamp, Arjen R., Miller, Austin, Montagna, Marco, Mukherjee, Semanti, Mulligan, Anna Marie, Nathanson, Katherine L., Neuhausen, Susan L., Nevanlinna, Heli, Niederacher, Dieter, Nielsen, Finn Cilius, Nikitina-Zake, Liene, Olah, Edith, Olopade, Olufunmilayo I., Osorio, Ana, Ott, Claus-Eric, Papi, Laura, Park, Sue K., Parsons, Michael T., Pedersen, Inge Sokilde, Peissel, Bernard, Peixoto, Ana, Peterlongo, Paolo, Pfeiler, Georg, Prajzendanc, Karolina, Pujana, Miquel Angel, Radice, Paolo, Ramser, Juliane, Ramus, Susan J., Rantala, Johanna, Rennert, Gad, Risch, Harvey A., Robson, Mark, Rønlund, Karina, Salani, Ritu, Senter, Leigha, Shah, Payal D., Sharma, Priyanka, Side, Lucy E., Singer, Christian F., Slavin, Thomas P., Soucy, Penny, Southey, Melissa C., Spurdle, Amanda B., Steinemann, Doris, Steinsnyder, Zoe, Sutter, Christian, Tan, Yen Yen, Teixeira, Manuel R., Teo, Soo Hwang, Thull, Darcy L., Tognazzo, Silvia, Toland, Amanda E., Trainer, Alison H., Tung, Nadine, van Engelen, Klaartje, van Rensburg, Elizabeth J., Vega, Ana, Vierstraete, Jeroen, Wagner, Gabriel, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weitzel, Jeffrey N., Yadav, Siddhartha, Yang, Xin, Yannoukakos, Drakoulis, Zimbalatti, Dario, Offit, Kenneth, Thomassen, Mads, Couch, Fergus J., Schmutzler, Rita K., Simard, Jacques, Easton, Douglas F., and Antoniou, Antonis C.

Published
2020
Full Text
View/download PDF

50. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials

Author

Pasalic, Dario, McGinnis, Gwendolyn J., Fuller, C. David, Grossberg, Aaron J., Verma, Vivek, Mainwaring, Walker, Miller, Austin B., Lin, Timothy A., Jethanandani, Amit, Espinoza, Andres F., Diefenhardt, Markus, Das, Prajnan, Subbiah, Vivek, Subbiah, Ishwaria M., Jagsi, Reshma, Garden, Adam S., Fokas, Emmanouil, Rödel, Claus, Thomas, Charles R., Jr., Minsky, Bruce D., and Ludmir, Ethan B.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results